Sir Richard Peto defends his Vytorin analysis
This article was originally published in Scrip
Executive Summary
The prominent Oxford University statistician Professor Sir Richard Peto has launched a strong defence of his conduct and his analyses of the cancer data from clinical studies of Merck/Schering-Plough's Vytorin (ezetimibe plus simvastatin) in response to a US congressional investigation, and repeated his conclusion that there is "no credible evidence" of any adverse effect of the product on cancer rates.